Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1758816 | 1.00 | FAAH (1.00) | FAAH | |
| Hydrochloric Acid SCHEMBL1759222 | 0.99 | FAAH (0.98) | FAAH | |
| SCHEMBL896175 | 0.92 | FAAH (1.00) | FAAH | |
| SCHEMBL1758812 | 0.91 | FAAH (1.00) | FAAH | |
| SCHEMBL897085 | 0.90 | FAAH (1.00) | FAAH | |
| SCHEMBL896840 | 0.90 | FAAH (1.00) | FAAH | |
| Hydrochloric Acid SCHEMBL1759016 | 0.90 | FAAH (0.98) | FAAH | |
| SCHEMBL896835 | 0.90 | FAAH (1.00) | FAAH | |
| SCHEMBL896169 | 0.89 | FAAH (1.00) | FAAH | |
| SCHEMBL896703 | 0.89 | FAAH (1.00) | FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250205175-A1 | Anti-Aging Composition with mTOR inhibitor for Humans and Other Mammals | POSTREL RICHARD (US) | 2025-06-26 | — | — | US | disclosed |
| US-20250152562-A1 | Compositions to Enhance and Extend Quality of Life | POSTREL RICHARD (US) | 2025-05-15 | — | — | US | disclosed |
| US-12280019-B2 | Anti-aging therapy for humans and other mammals | POSTREL RICHARD (US) | 2025-04-22 | — | — | US | disclosed |
| US-12220407-B2 | Life extension for humans and other mammals | POSTREL RICHARD (US) | 2025-02-11 | — | — | US | disclosed |
| US-12201589-B2 | Anti-aging therapy for canines and other domesticated animals | POSTREL RICHARD (US) | 2025-01-21 | — | — | US | disclosed |
| US-12201590-B2 | Extending human life with non-invasive mTOR inhibitor compositions | POSTREL RICHARD (US) | 2025-01-21 | — | — | US | disclosed |
| US-12194020-B2 | Reversing baldness through cannabinoid receptor activation | POSTREL RICHARD (US) | 2025-01-14 | — | — | US | disclosed |
| US-12115135-B2 | Anti-aging therapy for canines and other domesticated animals | REVIGORON LLC | 2024-10-15 | — | — | US | disclosed |
| US-20240216295-A1 | Anti-Aging Therapy for Humans and Other Mammals | POSTREL RICHARD (US) | 2024-07-04 | — | — | US | disclosed |
| US-20230404942-A1 | Life Extension and Quality of Life Improvement for Humans | POSTREL RICHARD (US) | 2023-12-21 | — | — | US | disclosed |
| US-20230114740-A1 | Life Extension and Quality of Life Improvement for Humans and Other Mammals | POSTREL RICHARD (US) | 2023-04-13 | — | — | US | disclosed |
| US-20220265646-A1 | PIEZO AGONISTS FOR PREVENTING OR REVERTING ABNORMAL AMYLOID DEPOSITION | ITÄ-SUOMEN YLIOPISTO (FI) | 2022-08-25 | — | — | US | disclosed |
| US-20220249434-A1 | Reversal of Baldness in Men and Women through Cannabinoid Receptor Activation | POSTREL RICHARD (US) | 2022-08-11 | — | — | US | disclosed |
| US-20220175694-A1 | Anti-Aging Therapy for Canines and Other Domesticated Animals | POSTREL RICHARD (US) | 2022-06-09 | — | — | US | disclosed |
| EP-3996702-A1 | PIEZO AGONISTS FOR PREVENTING OR REVERTING ABNORMAL AMYLOID DEPOSITION | Itä-Suomen Yliopisto (FI) | 2022-05-18 | — | — | EP | disclosed |
| US-11331300-B2 | Reversing baldness through follicle regeneration | POSTREL RICHARD (US) | 2022-05-17 | — | — | US | disclosed |
| US-11318093-B2 | Dental topical anesthetic gel | PAC-DENT, INC. | 2022-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220265646-A1 | PIEZO AGONISTS FOR PREVENTING OR REVERTING ABNORMAL AMYLOID DEPOSITION | PIEZO1, STIM2, ADRA1D | FAAH 2921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.